問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

顏家瑞

List

182Cases

2018-03-01 - 2020-12-31

Others

A PHASE Ib/III, OPEN-LABEL, MULTICOHORT, MULTICENTER, STUDY EVALUATING THE EFFICACY AND SAFETY OF RO6958688 PLUS ATEZOLIZUMAB, WITH OR WITHOUT CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

  • Condition/Disease

    METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

  • Test Drug

    RO6958688、Tecentriq、Onivyde、Leucovorin、Abraxane、Fluorouracil (5-FU)、Gemcitabine

Participate Sites
3Sites

Terminated3Sites

2020-07-01 - 2022-01-17

Phase I

A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors

  • Condition/Disease

    Malignant Solid Tumor

  • Test Drug

    SAR439459

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2018-06-01 - 2022-11-15

Phase I

A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With Atezolizumab or Isatuximab Alone in Patients With Advanced Malignancies

  • Condition/Disease

    Advanced Malignancies

  • Test Drug

    Isatuximab

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting5Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

余明隆
Kaohsiung Municipal Gangshan Hospital

未分科

2019-12-01 - 2022-12-31

Phase I/II

A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors

  • Condition/Disease

    Advanced Refractory Solid Tumors

  • Test Drug

    CS1001 Regorafenib

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2021-03-01 - 2023-05-31

Phase I

A Phase Ⅰ Study of the Safety, Tolerability, Pharmacokinetics Profile, and Preliminary Efficacy of TT-00434 in Patients with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    TT-00434

Participate Sites
3Sites

Not yet recruiting2Sites

Terminated1Sites

2015-01-01 - 2017-09-30

Phase III

An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck(SCCHN)

  • Condition/Disease

    Squamous Cell Cancer of the Head and Neck

  • Test Drug

    Nivolumab

Participate Sites
2Sites

Terminated2Sites

2011-07-01 - 2013-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

2015-06-01 - 2017-12-30

Phase II

An Open-Label, Phase II Study to Evaluate SCB01A in Patients with Recurrent or Metastatic Squamous Cell Head and Neck Cancer who have Received Platinum-Based Treatment

  • Condition/Disease

    Squamous Cell Head and Neck Cancer

  • Test Drug

    SCB01A

Participate Sites
6Sites

Terminated6Sites

2015-07-01 - 2019-03-31

Phase I

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients with Advanced Solid Tumours

  • Condition/Disease

    Advanced Solid Tumours

  • Test Drug

    MEDI4736

Participate Sites
3Sites

Not yet recruiting3Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-10-22 - 2019-12-31

Phase III

A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients

  • Condition/Disease

    Squamous Cell Head and Neck Cancer

  • Test Drug

    MEDI4736; Tremelimumab

Participate Sites
8Sites

Terminated7Sites

謝清昀
China Medical University Hospital-Taipei

未分科

楊慕華
Taipei Veterans General Hospital

Division of Otolaryngology

1 10 11 12 13 14 19
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB